12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vaxfectin-formulated tetravalent dengue DNA vaccine: Phase I started

Vical said the Naval Medical Research Center (NMRC) began a Phase I trial in about 40 subjects to compare low- and high-dose Vaxfectin-formulated tetravalent dengue DNA...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >